Pre- and Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer

Pre- and Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer

Neoadjuvant treatment (NAT) is one of the most widely used options for HER2+ and triple negative (TN) early breast cancer (BC). Since around half of the patients treated with NAT do not achieve a pathologically complete response (pCR), biomarkers to predict resistance are urgently needed. The correl...

Full description

Bibliographic Details
Main Authors: Laura Pons, Laura Hernández, Aintzane Urbizu, Paula Osorio, Paula Rodríguez-Martínez, Eva Castella, Ana Muñoz, Carolina Sanz, Laura Arnaldo, Eudald Felip, Vanesa Quiroga, Gustavo Tapia, Mireia Margelí, Pedro Luis Fernandez
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Cancers
Subjects:
breast cancer
neoadjuvant chemotherapy
HER2+
triple negative
Online Access:https://www.mdpi.com/2072-6694/15/12/3068

Internet

https://www.mdpi.com/2072-6694/15/12/3068

Similar Items